Skip to main content
Top
Published in: World Journal of Surgery 6/2012

01-06-2012

Level VI Lymph Node Dissection Does Not Decrease Radioiodine Uptake in Patients Undergoing Radioiodine Ablation for Differentiated Thyroid Cancer

Authors: Don Yoo, Saad Ajmal, Shilpa Gowda, Jason Machan, Jack Monchik, Peter Mazzaglia

Published in: World Journal of Surgery | Issue 6/2012

Login to get access

Abstract

Background

In patients with well-differentiated thyroid cancer, the incidence of pathologic central compartment lymph node metastases is reported to be approximately 50%. Recently level VI lymph node dissection has been advocated as a means of reducing recurrence rates in these patients, even if there are no clinically apparent nodal metastases. This study investigates whether level VI lymph node dissection decreases the percent radioiodine uptake when patients undergo radioiodine ablation.

Methods

All thyroid cancer patients entered into the endocrine surgery database at a tertiary care center from 2006 to 2010 were reviewed. Those treated with radioactive iodine were analyzed with respect to performance of a central compartment lymph node dissection and the percent uptake of radioiodine (131I) on the preablation scan at 72 h.

Results

There were 277 patients with well-differentiated thyroid cancer who underwent radioiodine ablation. In all, 75% were female, and the mean age was 47.7 years. A total of 87 patients underwent total thyroidectomy and level VI lymph node dissection (TT + LVIND). The mean number of level VI nodes resected was 6 (1–27), and 60.9% of patients had nodal metastases. Altogether, 190 had a total thyroidectomy (TT) only, and the median number of nodes resected was 0 (0–10). The percent uptake of radioiodine on the preablation scan was 0.93% in patients who had undergone TT + LVIND and 1.2% in those with TT alone (p = 0.17). The median number of radioactive foci noted within the thyroid bed was two in both groups (p = 0.64). The mean preablation thyroglobulin levels, measured after thyroxine withdrawal or thyrogen stimulation, were 4.0 ng/ml in the TT + LVIND group versus 4.7 ng/ml in the TT group (p = 0.07). The average ablative dose of 131I was 111.8 mCi in the dissection group and 98.5 mCi in the TT-only group.

Conclusions

There is no evidence that uptake of 131I is reduced by performance of a central neck dissection in patients with well-differentiated thyroid cancer. Preablation thyroglobulin levels were not altered by level VI lymph node dissection.
Literature
1.
go back to reference Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214PubMedCrossRef Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214PubMedCrossRef
2.
go back to reference Kouvaraki MA, Lee JE, Shapiro SE et al (2004) Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136:1183–1191PubMedCrossRef Kouvaraki MA, Lee JE, Shapiro SE et al (2004) Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136:1183–1191PubMedCrossRef
3.
go back to reference Henry JF, Gramatica L, Denizot A et al (1998) Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 383:167–169PubMed Henry JF, Gramatica L, Denizot A et al (1998) Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 383:167–169PubMed
4.
go back to reference Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428PubMedCrossRef Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428PubMedCrossRef
5.
go back to reference Sywak M, Cornford L, Roach P et al (2006) Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140:1000–1005 discussion 1005–1007PubMedCrossRef Sywak M, Cornford L, Roach P et al (2006) Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140:1000–1005 discussion 1005–1007PubMedCrossRef
6.
go back to reference Hughes DT, White ML, Miller BS et al (2010) Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148:1100–1106. discussion 1006–1007PubMedCrossRef Hughes DT, White ML, Miller BS et al (2010) Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148:1100–1106. discussion 1006–1007PubMedCrossRef
7.
go back to reference Pereira JA, Jimeno J, Miquel J et al (2005) Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138:1095–1100. discussion 1100–1101PubMedCrossRef Pereira JA, Jimeno J, Miquel J et al (2005) Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138:1095–1100. discussion 1100–1101PubMedCrossRef
8.
go back to reference Sawka AM, Thephamongkhol K, Brouwers M et al (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676PubMedCrossRef Sawka AM, Thephamongkhol K, Brouwers M et al (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676PubMedCrossRef
9.
go back to reference Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057 discussion 1057–1058PubMed Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057 discussion 1057–1058PubMed
10.
go back to reference Machens A, Hinze R, Thomusch O et al (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28PubMedCrossRef Machens A, Hinze R, Thomusch O et al (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28PubMedCrossRef
11.
go back to reference Wada N, Masudo K, Nakayama H et al (2008) Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age. Eur J Surg Oncol 34:202–207PubMedCrossRef Wada N, Masudo K, Nakayama H et al (2008) Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age. Eur J Surg Oncol 34:202–207PubMedCrossRef
13.
go back to reference Scheumann GF, Gimm O, Wegener G et al (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559–567. doi:10.1007/BF00353765 discussion 567–568PubMedCrossRef Scheumann GF, Gimm O, Wegener G et al (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559–567. doi:10.​1007/​BF00353765 discussion 567–568PubMedCrossRef
14.
go back to reference Bardet S, Malville E, Rame JP et al (2008) Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol 158:551–560PubMedCrossRef Bardet S, Malville E, Rame JP et al (2008) Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol 158:551–560PubMedCrossRef
15.
go back to reference Monchik JM, Simon CJ, Caragacianu DL et al (2009) Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid? Surgery 146:1182–1187PubMedCrossRef Monchik JM, Simon CJ, Caragacianu DL et al (2009) Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid? Surgery 146:1182–1187PubMedCrossRef
Metadata
Title
Level VI Lymph Node Dissection Does Not Decrease Radioiodine Uptake in Patients Undergoing Radioiodine Ablation for Differentiated Thyroid Cancer
Authors
Don Yoo
Saad Ajmal
Shilpa Gowda
Jason Machan
Jack Monchik
Peter Mazzaglia
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 6/2012
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-012-1507-2

Other articles of this Issue 6/2012

World Journal of Surgery 6/2012 Go to the issue